Respiporc Flu3
inactivated influenza-A virus / swine
Table of contents
Overview
Respiporc FLU3 is a vaccine that contains 3 different strains of swine influenza A virus which have been inactivated (killed). Respiporc FLU3 is a suspension for injection.
Respiporc FLU3 is used to vaccinate pigs including pregnant sows over the age of 56 days against swine influenza in order to help them clinically but also to reduce the amount of virus present in the lungs. Respiporc FLU3 is also used to vaccinate pregnant sows following their first immunisation by giving them one dose 14 days prior to farrowing in order that the sows milk contains enough antibodies to help protect the piglets against swine influenza for at least 33 days after birth.
Authorisation details
| Product details | |
|---|---|
| Name |
Respiporc Flu3
|
| Agency product number |
EMEA/V/C/000153
|
| Active substance |
inactivated influenza-A virus / swine
|
| International non-proprietary name (INN) or common name |
|
| Species |
Pigs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
CEVA Santé Animale
|
| Revision |
5
|
| Date of issue of marketing authorisation valid throughout the European Union |
14/01/2010
|
| Contact address |
10 avenue de La Ballastière |
Product information
15/09/2020 Respiporc Flu3 - EMEA/V/C/000153 - IG/1256/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Active immunisation of pigs from the age of 56 days onwards, including pregnant sows, against swine influenza caused by subtypes H1N1, H3N2 and H1N2 to reduce clinical signs and viral lung load after infection.
Onset of immunity: 7 days after primary vaccination
Duration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and 6 months in pigs vaccinated for the first time at 96 days and above.
Active immunisation of pregnant sows after finished primary immunisation by administration of a single dose 14 days prior to farrowing to develop high colostral immunity, which provides clinical protection of piglets for at least 33 days after birth.